Treat-to-target versus dose-adapted statin treatment of cholesterol to reduce cardiovascular risk.Show others and affiliations
2016 (English)In: European Journal of Preventive Cardiology, ISSN 2047-4873, E-ISSN 2047-4881, Vol. 23, no 3, p. 275-281Article in journal (Refereed) Published
Abstract [en]
Clinical guidelines should be based on the best available evidence and are of great importance for patient care and disease prevention. In this respect, the 2013 American College of Cardiology/American Heart Association report is highly appreciated and well-recognized. The report included critical questions concerning hypercholesterolaemia, but its translation into a clinical guideline initiated intense debate worldwide because of the recommendation to switch from a treat-to-target approach for low-density-lipoprotein-cholesterol to a statin dose-based strategy.
Place, publisher, year, edition, pages
2016. Vol. 23, no 3, p. 275-281
Keywords [en]
Hypercholesterolaemia; cardiovascular prevention
National Category
Cardiac and Cardiovascular Systems
Identifiers
URN: urn:nbn:se:liu:diva-124057DOI: 10.1177/2047487314567001ISI: 000369526800006PubMedID: 25595550OAI: oai:DiVA.org:liu-124057DiVA, id: diva2:895593
Note
Funding agencies:DMW: personal fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Merck Sharpe and Dohme, Novartis, Roche, Sanofi, Bayer, Janssen-Cilag, Lilly, NovoNordisk; non-financial support from Sanofi Germany, outside the submitted work. GA, RC, JD, EF, HG, AGO, WFR, ES: none. AVE: personal fees from Amgen Switzerland, Astra Zeneca Switzerland, Merck Sharpe and Dohme Switzerland, Sanofi Aventis, outside the submitted work; and member of the Executive Board of the European Atherosclerosis Society as well as the president of the Swiss Working Group on Lipids and Atherosclerosis (= Swiss Atherosclerosis Society), which both published own recommendations for the prevention of heart disease by lipid-lowering therapy.
2016-01-192016-01-192017-04-21